Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Takahiro KinamiShinsuke UchikawaTomokazu KawaokaShintaro YamasakiMasanari KosakaYusuke JohiraShigeki YanoKei AmiokaKensuke NarutoKenji YamaokaYasutoshi FujiiHatsue FujinoTakashi NakaharaAtsushi OnoEisuke MurakamiWataru OkamotoMasami YamauchiDaiki MikiMasataka TsugeShiro OkaPublished in: Cancer medicine (2024)
No significant differences in efficacy and safety were observed with PH. Prophylactic treatment for varices before the start of Atezo + Beva would allow treatment to continue relatively safely.